Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial)

European Journal of Cancer

Volumn 51, Issue 8, 2015, Pages 935-941

  Yoshida, M ^a   Muro, K ^b   Tsuji, A ^c   Hamamoto, Y ^d   Yoshino, T ^e   Yoshida, K ^f   Shirao, K ^g   Miyata, Y ^h   Takahari, D ^b   Takahashi, T ^f   Ohtsu, A ^e  

^a OSAKA MEDICAL COLLEGE HOSPITAL   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

^c Kochi Health Sciences Center   (Japan)

^d TOCHIGI CANCER CENTER   (Japan)

^e NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^f GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g OITA UNIVERSITY   (Japan)

^h Nagano Prefectural Federation of Agricultural Cooperative for Health and Welfare   (Japan)

Author keywords

Bevacizuma b; Colorectal cancer; Elderly; S 1

Indexed keywords

BEVACIZUMAB; CREATININE; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; OXALIPLATIN; TEGAFUR; ANTINEOPLASTIC AGENT; DRUG COMBINATION; MONOCLONAL ANTIBODY; OTERACIL; S 1 (COMBINATION);

AGED; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CHEMOTHERAPY INDUCED ANEMIA; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; ECG ABNORMALITY; EPISTAXIS; EVENING DOSAGE; FATIGUE; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; HUMAN TISSUE; HYPERBILIRUBINEMIA; HYPERTENSION; LEUKOPENIA; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MORNING DOSAGE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NEUTROPHIL COUNT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; SENESCENCE; STOMATITIS; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TIME TO TREATMENT; TUMOR BIOPSY; VERY ELDERLY; CARCINOMA; CLINICAL TRIAL; COLORECTAL NEOPLASMS; DOSE RESPONSE; DRUG COMBINATION; METASTASIS; MORTALITY; MULTICENTER STUDY; PATHOLOGY; SURVIVAL; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; NEOPLASM METASTASIS; OXONIC ACID; SURVIVAL ANALYSIS; TEGAFUR; TREATMENT OUTCOME;

EID: 84928978561     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2015.03.007     Document Type: Article

References (24)

1. V. Heinemann, L.F. von Weikersthal, T. Decker, A. Kiani, U. Vehling-Kaiser, and S.E. Al-Batran FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial Lancet Oncol 15 10 2014 1065 1075
2. F. Loupakis, C. Cremolini, G. Masi, S. Lonardi, V. Zagonel, and L. Salvatore Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer N Engl J Med 371 17 2014 1609 1618
3. L.B. Saltz, S. Clarke, E. Diaz-Rubio, W. Scheithauer, A. Figer, and R. Wong Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol 26 12 2008 2013 2019
4. A. Figer, N. Perez-Staub, E. Carola, C. Tournigand, G. Lledo, and M. Flesch FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer: an exploratory cohort of the OPTIMOX1 study Cancer 110 12 2007 2666 2671
5. H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth, and W. Heim Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 23 2004 2335 2342
6. N.A. Jackson, J. Barrueco, R. Soufi-Mahjoubi, J. Marshall, E. Mitchell, and X. Zhang Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study Cancer 115 12 2009 2617 2629
7. F.F. Kabbinavar, J. Hambleton, R.D. Mass, H.I. Hurwitz, E. Bergsland, and S. Sarkar Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer J Clin Oncol 23 16 2005 3706 3712
8. C. Tournigand, A. Cervantes, A. Figer, G. Lledo, M. Flesch, and M. Buyse OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer-a GERCOR study J Clin Oncol 24 3 2006 394 400
9. F. Kabbinavar, H.I. Hurwitz, L. Fehrenbacher, N.J. Meropol, W.F. Novotny, and G. Lieberman Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer J Clin Oncol 21 1 2003 60 65
10. F.F. Kabbinavar, J. Schulz, M. McCleod, T. Patel, J.T. Hamm, and J.R. Hecht Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial J Clin Oncol 23 16 2005 3697 3705
11. D. Cunningham, I. Lang, E. Marcuello, V. Lorusso, J. Ocvirk, and D.B. Shin Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial Lancet Oncol 14 11 2013 1077 1085
12. T. Shirasaka, Y. Shimamato, H. Ohshimo, M. Yamaguchi, T. Kato, and K. Yonekura Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators Anticancer Drugs 7 5 1996 548 557
13. K. Shirao, A. Ohtsu, H. Takada, Y. Mitachi, K. Hirakawa, and N. Horikoshi Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma Cancer 100 11 2004 2355 2361
14. A. Ohtsu, H. Baba, Y. Sakata, Y. Mitachi, N. Horikoshi, and K. Sugimachi Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group Br J Cancer 83 2 2000 141 145
15. Y. Yamada, D. Takahari, H. Matsumoto, H. Baba, M. Nakamura, and K. Yoshida Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial Lancet Oncol 14 13 2013 1278 1286
16. [Japanese translation of common terminology criteria for adverse events (CTCAE), and instructions and guidelines]. Int J Clin Oncol 2004;9(Suppl. 3):1-82.
17. P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, and L. Rubinstein New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 3 2000 205 216
18. C.H. Kohne, D. Cunningham, F. Di Costanzo, B. Glimelius, G. Blijham, and E. Aranda Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients Ann Oncol 13 2 2002 308 317
19. Y.S. Hong, Y.S. Park, H.Y. Lim, J. Lee, T.W. Kim, and K.P. Kim S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial Lancet Oncol 13 11 2012 1125 1132
20. K. Muro, N. Boku, Y. Shimada, A. Tsuji, S. Sameshima, and H. Baba Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study) Lancet Oncol 11 9 2010 853 860
21. M.T. Seymour, T.S. Maughan, J.A. Ledermann, C. Topham, R. James, and S.J. Gwyther Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial Lancet 370 9582 2007 143 152
22. M. Koopman, N.F. Antonini, J. Douma, J. Wals, A.H. Honkoop, and F.L. Erdkamp Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial Lancet 370 9582 2007 135 142
23. M. Ducreux, D. Malka, J. Mendiboure, P.L. Etienne, P. Texereau, and D. Auby Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial Lancet Oncol 12 11 2011 1032 1044
24. R. Yancik, M.N. Wesley, L.A. Ries, R.J. Havlik, S. Long, and B.K. Edwards Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: a population-based study Cancer 82 11 1998 2123 2134